Effect of red clover isoflavones on Cox-2 activity in murine and human monocyte/macrophage cells

Nutrition and Cancer

Volumn 49, Issue 1, 2004, Pages 89-93

  Lam, Anna N C ^a   Demasi, Maryanne ^b   James, Michael J ^b   Husband, Alan J ^a   Walker, Catherine ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c Novogen Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHANIN A; CYCLOOXYGENASE 2; DAIDZEIN; FORMONONETIN; GENISTEIN; ISOFLAVONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; THROMBOXANE B2;

ANIMAL CELL; ARTICLE; BEAN; CANCER INCIDENCE; CELL ASSAY; CELL LINE; CELL STRAIN RAW 264.7; DIET SUPPLEMENTATION; ENZYME INHIBITION; FOOD INTAKE; HUMAN; HUMAN CELL; LEGUME; LENTIL; MACROPHAGE; MONOCYTE; NONHUMAN; PEA; PLANT PRODUCT; PROSTAGLANDIN SYNTHESIS INHIBITION; RED CLOVER;

ANIMALIA; LENS CULINARIS; MURINAE; PHASEOLUS (ANGIOSPERM); PISUM SATIVUM; TRIFOLIUM; TRIFOLIUM PRATENSE;

EID: 4644311473     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc4901_12     Document Type: Article

References (43)

1. Moran EM: Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 21, 193-201, 2002.
2. Husain SS, Szabo IL, and Tamawski AS: NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J of Gastroenterol 97, 542-553, 2002.
3. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, and Heath CW: Aspirin use and risk of fatal cancer. [comment]. Cancer Res 53, 1322-1327, 1993.
4. Harris RE, Namboodiri KK, and Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7, 203-205, 1996.
5. Chiu CH, McEntee MF, and Whelan J: Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+) mice. Prostaglandins Leukot Essent Fatty Acids 62, 269-275, 2000.
6. Jacoby RF, Seibert K, Cole CE, Kelloff G, and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60, 5040-5044, 2000.
7. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, et al.: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Japanese J Cancer Res 91, 886-892, 2000.
8. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, et al.: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117, 838-847, 1999.
9. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, et al.: Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 90, 406-412, 1999.
10. Zweifel BS, Davis TW, Ornberg RL, and Masferrer JL: Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 62, 6706-6711, 2002.
11. Howe LR, Subbaramaiah K, et al.: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 8, 97-114, 2001.
12. Dempke W, Rie C, Grothey A, and Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127, 411-417, 2001.
13. Marx J: Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science 291, 581-582, 2001.
14. Duan W, Kuo IC, Selvarajan S, Chua KY, Bay BH, et al.: Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am J Respir Crit Care Med 167, 185-192, 2003.
15. Jacobson KA, Moro S, Manthey JA, West PL, and Ji XD: Interactions of flavones and other phytochemicals with adenosine receptors. Adv Exp Med Biol 505, 163-171, 2002.
16. Middleton E Jr, Kandaswami C, and Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52, 673-751, 2000.
17. Beck V, Unterrieder E, Krenn L, Kubelka W, and Jungbauer A: Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 84, 259-268, 2003.
18. Blanco A, Habib A, Levy-Toledano S, and Maclouf J: Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem J 312(Pt 2), 419-423, 1995.
19. Liang YC, Huang YT, Tsai DC, Lin-Shiau SY, and Lin JK: Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20, 1945-1952, 1999.
20. You KM, Jong HG, and Kim HP: Inhibition of cyclooxygenase/lipoxygenase from human platelets by polyhydroxylated/methoxylated flavonoids isolated from medicinal plants. Arch Pharmacol Res 22, 18-24, 1999.
21. Chen YC, Shen SC, Lee WR, Hou WC, Yang LL, et al.: Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 82, 537-548, 2001.
22. Jiang Q, Elson-Schwab I, Courtemanche C, and Ames BN: gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 97, 11494-11499, 2000.
23. Bass RJ: Synthesis of chromones by cyclization of 2-hydroxyphenyl ketones with boron trifluoride-diethyl ether and methanesulphonyl chloride. J Chem Soc Chem Communications 2, 33-80, 1976.
24. Demasi M, Caughey GE, James MJ, and Cleland LG: Assay of cyclooxygenase-1 and 2 in human monocytes. Inflamm Res 49, 737-743, 2000.
25. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2), 55-63, 1983.
26. Caughey, GE, Pouliot M, Cleland LG, and James, MJ: Regulation of tumour necrosis factor-alpha and IL-beta sythesis by thromboxane A2 in nonadherent human monocytes. J Immunol 158, 351-358, 1997.
27. Penglis PS, Cleland LG, Demasi M, Caughey GE, and James MJ: Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: Implications for the use of cyclooxygenase inhibitors. J Immunol 165, 1605-1611, 2000.
28. Izzo AA and Capasso F: Herbal medicine, cancer prevention and cyclooxygenase 2 inhibition. Trends Pharmacol Sci 24, 218-219, 2003.
29. Adlercreutz H and W Mazur: Phyto-oestrogens and Western diseases. Ann Med 29, 95-120, 1997.
30. Su SJ, Yeh TM, Lei HY, and Chow NH: The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 6, 230-236, 2000.
31. Gotoh T, Yamada K, Yin H, Ito A, Kataoka T, et al.: Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Jpn J Cancer Res 89, 137-142, 1998.
32. Onozawa M, Kawamori T, Baba M, Fukuda K, Toda T, et al.: Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 90, 393-398, 1999.
33. Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB, et al.: Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutrition & Cancer 41(1-2), 75-81, 2001.
34. Barnes S: Effect of genistein on in vitro and in vivo models of cancer. Journal of Nutrition 125(3 Suppl), 777S-783S, 1995.
35. Shao ZM, Wu J, Shen ZZ, and Barsky SH: Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58, 4851-4857, 1998.
36. Barnes S, Peterson TG, and Coward L: Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem - Supplement 22, 181-187, 1995.
37. Shao ZM, Shen ZZ, Fontana JA, and Barsky SH: Genistein's ER-dependent and independent actions are mediated through ER pathways in ER-positive breast carcinoma cell lines. Anticancer Res 20, 2409-2416, 1995.
38. Cotroneo MS, Wang J, Fritz WA, Eltoum IE, and Lamartiniere CA: Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis 23, 1467-1474, 2002.
39. Wang W, Higuchi CM, and Zhang R: Individual and combinatory effects of soy isoflavones on the in vitro potentiation of lymphocyte activation. Nutr Cancer 29, 29-34, 1997.
40. Zhang R, Li Y, and Wang W: Enhancement of immune function in mice fed high doses of soy daidzein. Nutr Cancer 29, 24-28, 1997.
41. Setchell KD: Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68(6 Suppl), 1333S-1346S, 1998.
42. Mitchell JH, Cawood E, Kinniburgh D, Provan A, Collins AR, et al.: Effect of a phytoestrogen food supplement on reproductive health in normal males. Clin Sci 100, 613-618, 2001.
43. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, et al.: Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 133, 1027-1035, 2003.